Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,513.98
(
0.94%
)
US TECH 100
28,861.60
(
0.96%
)
Dow Jones
50,134.43
(
0.89%
)
Brent Oil
102.57
(
-1.08%
)
Bitcoin
81,437.75
(
2.72%
)
News Focus
News Focus
Post# of 257560
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122977
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 142518

Thursday, 05/24/2012 10:16:12 AM

Thursday, May 24, 2012 10:16:12 AM

Post# of 257560
Importantly for MNTA investors, Teva did not lower its guidance for 2012 Copaxone sales; rather Teva’s guidance remains at $3.8B, which suggests US Copaxone sales of approximately $2.6B (#msg-75407657). The $2.6B figure assumes no generic entry in the market, of course.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today